Your session is about to expire
← Back to Search
Inclisiran Sodium for High Cholesterol (ORION-8 Trial)
ORION-8 Trial Summary
This trial will study the long-term effects of Inclisiran, a drug used to treat high cholesterol. The trial will be conducted at multiple centers around the world.
- High Cholesterol
- Hypercholesterolemia
- Cardiovascular Disease
ORION-8 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowORION-8 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 3 trial • 1561 Patients • NCT03399370ORION-8 Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any other ongoing research projects that utilize Inclisiran Sodium?
"There are 11 ongoing trials for Inclisiran Sodium, with the majority of them being Phase 3 trials. The trials are being conducted in 1407 locations, with the most Inclisiran Sodium trials taking place in Bayamon and Gauteng."
Does Inclisiran Sodium have FDA backing?
"Given that this is a Phase 3 trial with some data supporting efficacy and multiple rounds of data supporting safety, Inclisiran Sodium is estimated to be a 3 on Power's Safety Scale."
What are some of the conditions that Inclisiran Sodium is regularly used to treat?
"Inclisiran Sodium is used to lower cholesterol levels in patients with primary hypercholesterolemia. It can also help those with diet-related hypercholesterolemia and atherosclerotic cardiovascular diseases."
Are there any more positions available for patients in this experiment?
"This specific trial is not looking for patients at this moment, however, according to the latest information from clinicaltrials.gov, which was last updated on January 26th, 2022, this could change in the future. Additionally, there are 86 other studies that are actively recruiting patients."
What are some other examples of this type of clinical research?
"Inclisiran Sodium has been researched since 2018. The initial trial was conducted in 2018 and was sponsored by Novartis Pharmaceuticals. Following the first trial in 2018, which involved 15000, Inclisiran Sodium received its Phase 3 drug approval. Today there are 11 live studied for Inclisiran Sodium across 587 cities and 51 countries."
How many people are a part of this clinical study?
"This study is not recruiting at this moment. The listing was initially posted on 2019-04-16 and was updated on 2022-01-26. There are presently 75 studies actively admitting patients with ascvd and 11 trials for Inclisiran Sodium actively enrolling participants."
Who else is applying?
What state do they live in?
How old are they?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger